Escitalopram (Lexapro) Has Substantially More Evidence for Managing Anxiety
Escitalopram is the clear choice for anxiety disorders based on significantly stronger evidence, established guideline support, and proven efficacy across multiple anxiety conditions, while vilazodone (Viibryd) has limited anxiety-specific data and is FDA-approved only for major depressive disorder.
Evidence Quality and Guideline Support
Escitalopram's Strong Position
Multiple international guidelines specifically recommend escitalopram as a first-line treatment for anxiety disorders. The Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology guidelines 1 list escitalopram among the SSRIs covered by national health insurance for social anxiety disorder. The NICE guidelines in the UK list escitalopram and sertraline as first-line pharmacotherapy for social anxiety disorder 1. The Canadian Clinical Practice Guidelines similarly include escitalopram as a first-line drug for anxiety disorders 1.
A 2019 network meta-analysis of first-line drugs for generalized anxiety disorder (GAD) found escitalopram demonstrated superior efficacy with a weighted mean difference of -3.2 on the Hamilton Anxiety Scale (95% CrI = -4.2 to -2.2), making it one of the most effective agents studied 2. The analysis concluded that duloxetine and escitalopram showed the best efficacy among all agents examined 2.
Vilazodone's Limited Anxiety Evidence
Vilazodone is FDA-approved only for major depressive disorder, not anxiety disorders 3. The clinical trials supporting its approval studied depression using the MADRS scale, not anxiety-specific outcomes 3.
Only one placebo-controlled trial specifically examined vilazodone for GAD 4. In this study, vilazodone 40 mg/day showed statistical significance versus placebo on the Hamilton Anxiety Scale (-1.80 difference, P = .0312), but this effect was notably weaker than escitalopram's demonstrated efficacy. Importantly, vilazodone 20 mg/day failed to separate from placebo 4. The same network meta-analysis that favored escitalopram found vilazodone had the weakest efficacy among active drugs (weighted mean difference -1.8,95% CrI = -3.1 to -0.55) and was the only agent with significantly worse acceptability than placebo (OR = 1.7,95% CrI = 1.1 to 2.7) 2.
Head-to-Head Comparison Data
Two small head-to-head studies compared vilazodone to escitalopram, but both studied depression, not anxiety:
- A 4-week rater-blinded trial (n=52) found no significant difference in depression scores, though vilazodone had significantly more diarrhea 5
- A 12-week open-label study (n=60) showed comparable antidepressant efficacy 6
Neither study provides meaningful data for anxiety treatment decisions.
Clinical Algorithm for Anxiety Treatment Selection
Start with escitalopram 10-20 mg daily for any anxiety disorder based on:
- Established first-line guideline recommendations across multiple international societies
- Superior efficacy data in network meta-analysis
- FDA approval for multiple anxiety indications (though the label focuses on depression, extensive evidence supports anxiety use)
- Better tolerability profile compared to vilazodone
Consider vilazodone only if:
- Patient has failed multiple SSRIs including escitalopram
- Patient has comorbid depression as the primary diagnosis
- You are willing to titrate to 40 mg (the 20 mg dose failed to beat placebo for anxiety)
- Patient accepts higher risk of gastrointestinal side effects, particularly diarrhea (reported in ≥5% and at least twice the rate of placebo) 4
Key Caveats
The most significant pitfall would be choosing vilazodone for anxiety based on its antidepressant approval or marketing. Vilazodone lacks FDA approval for any anxiety disorder and has minimal supporting evidence 3. The single positive GAD trial showed modest efficacy only at the 40 mg dose, with worse tolerability than placebo 4.
Escitalopram has decades of evidence, multiple anxiety disorder indications in clinical practice, and consistent guideline support. While vilazodone may have theoretical advantages through its 5-HT1A partial agonist activity, this has not translated into superior anxiety outcomes in clinical trials 2, 4.